What is Labcorp Holdings Inc. stock?
LH is the ticker symbol for Labcorp Holdings Inc., listed on NYSE.
Founded in 1995 and headquartered in Burlington, Labcorp Holdings Inc. is a Medical/Nursing Services company in the Health services sector.
What you'll find on this page: What is LH stock? What does Labcorp Holdings Inc. do? What is the development journey of Labcorp Holdings Inc.? How has the stock price of Labcorp Holdings Inc. performed?
Last updated: 2026-05-20 22:31 EST
About Labcorp Holdings Inc.
Quick intro
Labcorp Holdings Inc. is a global leader in comprehensive laboratory services, providing diagnostic testing, drug development, and clinical trial laboratory solutions to patients, physicians, hospitals, pharmaceutical companies, and researchers. Headquartered in Burlington, North Carolina, Labcorp operates an extensive network of laboratories and patient service centers across the United States and internationally.
In fiscal 2025, Labcorp delivered over 7% revenue growth and 13% adjusted EPS growth, with operating margins improving by over 50 basis points. The company serves approximately 70% of U.S. hospitals and processes billions of lab tests annually.
Basic info
Labcorp Holdings Inc. Business Introduction
Labcorp Holdings Inc. (NYSE: LH), commonly known as Labcorp, is a global leader in innovative and comprehensive laboratory services. The company plays a vital role in the healthcare ecosystem by providing vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Headquartered in Burlington, North Carolina, Labcorp operates one of the largest clinical laboratory networks in the world.
Detailed Business Segment Introduction
Following the spin-off of its clinical development business (Fortrea) in 2023, Labcorp has streamlined its operations into two primary segments:
1. Labcorp Diagnostics (Dx): This is the company's core segment, contributing the vast majority of its revenue. It operates a massive network of primary and specialty laboratories.
- Routine Testing: Includes standard blood chemistry, urinalysis, and blood cell counts used in general health screenings.
- Genomic and Esoteric Testing: High-end testing for complex diseases, including oncology, infectious diseases (like HIV/Hepatitis), and genetic disorders.
- Anatomic Pathology: Microscopic examination of tissues and cells to diagnose cancer and other diseases.
2. Labcorp Biopharma Laboratory Services (BLS): This segment provides essential support to the pharmaceutical, biotechnology, and medical device industries.
- Central Lab Services: Standardizing laboratory testing for global clinical trials to ensure data consistency across multiple study sites.
- Early Development Research: Providing non-clinical testing and specialized services to support the transition of drug candidates from the lab to human trials.
Business Model Characteristics
Scale-Driven Efficiency: Labcorp utilizes a "Hub-and-Spoke" model. Large automated central labs (hubs) process high volumes of tests from regional patient service centers (spokes), significantly lowering the cost per test through economies of scale.
Payer Diversification: Revenue is sourced from a mix of managed care organizations, Medicare/Medicaid, direct-to-patient payments, and pharmaceutical companies, reducing reliance on any single funding source.
Integrated Data Ecosystem: With access to billions of lab results, Labcorp leverages its data to provide insights for drug development and population health management.
Core Competitive Moat
· Unrivaled Scale and Network: Labcorp operates over 2,000 patient service centers and processes approximately 2.5 million specimens per week. This physical footprint is nearly impossible for new entrants to replicate.
· High Switching Costs: Integration with physician Electronic Health Record (EHR) systems and long-term contracts with health insurance providers create significant stickiness.
· Technological Leadership: Investments in digital pathology, AI-driven diagnostics, and at-home collection kits (Pixel by Labcorp) keep the company at the forefront of medical innovation.
Latest Strategic Layout
Labcorp is currently focusing on High-Growth Specialty Areas. In 2024 and 2025, the company has aggressively expanded its oncology and neurology testing capabilities. Furthermore, Labcorp is pursuing a "Hospital Lab Management" strategy, where it enters into long-term partnerships or acquisitions of health system laboratories (e.g., the acquisition of select assets from Baystate Health and Providence), allowing hospitals to outsource complex lab operations to Labcorp for better efficiency.
Labcorp Holdings Inc. Development History
Labcorp’s journey is a story of strategic consolidation and technological evolution, transforming from a regional lab into a global diagnostic powerhouse.
Key Development Stages
1. The Foundation (1969 - 1994):
The company traces its roots to Biomedical Methods, Inc., founded in 1969 by the Powell brothers in a former hospital basement in North Carolina. It later became Biomedical Reference Laboratories and eventually merged with Roche's clinical lab business (Roche Biomedical Laboratories) in 1995 to form the modern **Laboratory Corporation of America Holdings**.
2. The Expansion Era (1995 - 2013):
During this period, Labcorp focused on horizontal expansion. It acquired numerous regional labs across the United States to build its nationwide network. Key milestones included the early adoption of genomic testing and the acquisition of Dynacare in 2002, which expanded its footprint into Canada.
3. The Diversification Pivot (2014 - 2022):
A transformative moment occurred in 2015 when Labcorp acquired **Covance** for $6.1 billion. This moved the company beyond simple diagnostics into the Contract Research Organization (CRO) space, allowing it to support the entire drug development lifecycle from "bench to bedside."
4. Streamlining for Value (2023 - Present):
In 2023, Labcorp completed the spin-off of its Clinical Development business into a separate public entity called **Fortrea**. This allowed Labcorp to refocus on its core laboratory operations and high-growth biopharma lab services, resulting in a more specialized and agile corporate structure.
Analysis of Success Factors
Strategic Consolidation: Labcorp successfully navigated the highly fragmented lab industry by acquiring smaller competitors, allowing them to dominate through volume and logistics.
Early Adoption of Specialized Testing: By investing in molecular and genetic testing early, Labcorp moved up the value chain from "commodity" routine tests to high-margin specialized diagnostics.
Adaptability: During the COVID-19 pandemic, Labcorp’s rapid scaling of testing capabilities demonstrated its operational excellence and cemented its role as a critical piece of national healthcare infrastructure.
Industry Introduction
Labcorp operates within the Clinical Laboratory Services and Biopharmaceutical Services industries. This sector is characterized by high barriers to entry due to regulatory requirements (CLIA, CAP) and the necessity of massive logistical networks.
Industry Trends and Catalysts
· Precision Medicine: The shift toward personalized treatments requires advanced genetic and companion diagnostic testing, driving higher demand for Labcorp's specialty services.
· Aging Population: As the global population ages, the prevalence of chronic diseases increases, leading to a steady rise in the volume of routine monitoring and diagnostic tests.
· Consumerization of Healthcare: Patients are increasingly seeking direct access to lab tests and at-home collection options, a trend Labcorp is capturing through its digital platforms.
Competitive Landscape
Key Competitor Market Position Primary Strength| Quest Diagnostics | Primary Rival | Largest domestic US footprint; strong direct-to-consumer presence. |
| OPKO Health (BioReference) | Specialized Competitor | Focus on oncology and urology niche markets. |
| Hospital-Affiliated Labs | Localized Competitors | Direct access to inpatient volume; however, many are now outsourcing to Labcorp. |
| In-house Pharma Labs | Internal Competition | Large pharma companies sometimes perform early-stage testing internally. |
Industry Status and Market Data
The global clinical laboratory services market is estimated to be valued at approximately $220 billion to $250 billion, with a projected CAGR of 5-6% through 2030. Labcorp and Quest Diagnostics together hold a significant portion of the independent lab market in the U.S.
Market Position: Labcorp is consistently ranked as one of the top two independent clinical laboratories in the world. With its 2023 revenue exceeding $12 billion (post-spin-off), Labcorp maintains a "Wide Moat" rating from analysts due to its pricing power with payers and its essential role in the clinical trial supply chain.
Sources: Labcorp Holdings Inc. earnings data, NYSE, and TradingView
Labcorp Holdings Inc. Financial Health Score
Labcorp Holdings Inc. (NYSE: LH) is a global leader in laboratory diagnostics and clinical research services, operating two primary segments: Diagnostics (clinical laboratory testing) and Biopharma Laboratory Services (drug development support). The following scorecard is based on FY2025 results.
| Dimension | Score (40–100) | Stars | Commentary |
|---|---|---|---|
| Revenue Growth | 72 | ⭐⭐⭐⭐ | FY2025 revenue of $13.95B, up from $13.01B — approximately 7% growth YoY. Q4 2025 revenue of $3.52B with 5.6% growth. Management guided for 4.7%–6% enterprise revenue growth in 2026, reflecting sustained momentum. |
| Profitability | 74 | ⭐⭐⭐⭐ | FY2025 diluted EPS of $10.46, up from $8.84 — 18.3% growth. Double-digit adjusted EPS growth with margin expansion demonstrates strong operational leverage. Profitability is improving consistently year over year. |
| Balance Sheet Strength | 62 | ⭐⭐⭐ | Year-end cash of $532.3M against total debt of $5.58B. Leverage ratio of 2.3x gross debt to trailing twelve-month adjusted EBITDA is manageable but elevated relative to investment-grade healthcare peers. The leverage reflects historical M&A activity. |
| Cash Flow Health | 71 | ⭐⭐⭐⭐ | Strong operating cash flow generation supports debt service and capital allocation. The company has demonstrated consistent free cash flow conversion, enabling both M&A investment and shareholder returns through dividends and buybacks. |
| Return on Equity (ROE) | 68 | ⭐⭐⭐ | ROE is solid but moderated by the company's substantial goodwill and intangible assets from acquisitions, which inflate the equity base. Underlying returns on tangible equity are more attractive. |
| Valuation Reasonableness | 76 | ⭐⭐⭐⭐ | With a consensus Buy rating and average price target of $303–$311 vs. current price near $260, LH appears attractively valued with approximately 20% implied upside. The stock trades at a discount to healthcare sector peers given its leverage profile. |
Labcorp Holdings Inc. Development Potential
Biopharma Laboratory Services Growth
Labcorp's Biopharma Laboratory Services segment supports pharmaceutical and biotech companies throughout the drug development lifecycle, from early clinical trials to commercial launch. As global pharmaceutical R&D spending continues to grow and the biotech pipeline expands, this segment provides a structural tailwind. Labcorp has invested in expanding its central laboratory capabilities, genomics services, and specialty testing to capture a larger share of growing clinical trial outsourcing budgets.
Diagnostics Innovation and Automation
The Diagnostics segment is investing in laboratory automation, artificial intelligence-driven diagnostic interpretation, and expanded specialty testing menus. AI-powered pathology and genomic testing represent high-growth, high-margin opportunities that can differentiate Labcorp from commodity testing competitors. The company's scale — processing millions of tests annually — provides a significant data advantage for AI model training and validation.
Acquisitions and Market Consolidation
Labcorp has historically grown through strategic acquisitions, and the laboratory services industry remains fragmented with consolidation opportunities. Management has indicated ongoing interest in bolt-on acquisitions that expand geographic reach, add specialty testing capabilities, or strengthen the biopharma services platform.
2026 Revenue Growth Guidance
Management's 2026 guidance for 4.7%–6% enterprise revenue growth provides near-term visibility and reflects confidence in both segment trajectories. This above-market growth rate, combined with ongoing margin expansion, supports a compelling earnings growth profile.
Labcorp Holdings Inc. Company Positives & Risks
Bullish Factors
1. Consistent Revenue and EPS Growth: FY2025 revenue grew 7% to $13.95B, and diluted EPS grew 18.3% to $10.46, demonstrating strong operational leverage and execution.
2. Defensive Business Model: Laboratory diagnostics is a necessity-driven healthcare service with relatively inelastic demand, providing revenue stability through economic cycles.
3. Buy Consensus with 20% Upside: With a consensus Buy rating and average analyst target of $303–$311 vs. current price near $260, the market appears to undervalue LH's earnings growth trajectory.
4. Biopharma Services Tailwind: Growing pharmaceutical R&D outsourcing and expanding clinical trial activity provide a secular growth driver for the high-margin Biopharma Laboratory Services segment.
5. Margin Expansion Track Record: Consistent margin improvement through operational efficiency, automation, and mix shift toward higher-margin specialty and biopharma testing.
Risk Factors
1. Elevated Leverage: A 2.3x debt-to-EBITDA leverage ratio and $5.58B in total debt against only $532M in cash creates financial risk if earnings disappoint or credit conditions tighten.
2. Regulatory and Reimbursement Risk: Laboratory testing reimbursement rates are subject to CMS (Centers for Medicare & Medicaid Services) policy changes, which can reduce revenue per test for the Diagnostics segment.
3. Competitive Pressure from Quest Diagnostics: Quest Diagnostics (DGX) is LABCORP's primary competitor in clinical laboratory testing, and intense price competition in the routine testing market can pressure margins.
4. Biopharma Services Cyclicality: Clinical trial outsourcing demand is influenced by pharmaceutical industry R&D budgets, which can be cut during periods of biotech funding stress or drug pipeline disappointments.
5. Integration and M&A Execution Risk: Labcorp's growth-by-acquisition strategy creates integration complexity and goodwill impairment risk if acquired businesses underperform.
How Do Analysts View Labcorp Holdings Inc. and LH Stock?
Core Institutional Views
Wall Street is broadly bullish on Labcorp Holdings, with the consensus reflecting confidence in the company's consistent revenue and earnings growth trajectory, defensive business characteristics, and improving margin profile. Analysts at major institutions view LH as a high-quality healthcare services compounder with a durable competitive moat in laboratory diagnostics and a growing, higher-margin biopharma services franchise.
JPMorgan has been among the most bullish, issuing a price target of $330 as of February 2026, reflecting confidence in Labcorp's earnings growth trajectory and the undervaluation of its biopharma services segment. Analysts across institutions highlight the company's 7% revenue growth in FY2025 and 18.3% EPS growth as evidence of strong operational execution. The consensus view is that Labcorp is executing well on its strategic priorities of growing specialty testing, expanding biopharma services, and improving operational efficiency through automation.
Stock Ratings & Price Targets
The analyst consensus on LH is Buy. StockAnalysis reports 9 analysts with a consensus Buy rating and an average price target of $311.33, implying approximately 20% upside from current levels. TipRanks data shows an average target of $303.80 from 11 analysts, with the high at $325.00 and the low at $270.00. Benzinga reports a broader consensus target of $284.05 from 23 analysts, with JPMorgan's $330 target as the most bullish. The relatively tight range of targets — especially among the most recent ratings — reflects broad analyst agreement on LH's fundamental quality and growth outlook.
Analyst Risk Highlights
The primary risk highlighted by more cautious analysts, including Deutsche Bank (which issued a $230 target in August 2024), is Labcorp's elevated leverage profile. With $5.58 billion in total debt and a 2.3x debt-to-EBITDA leverage ratio, any earnings disappointment or credit market tightening could create balance sheet pressure. Some analysts have also flagged regulatory reimbursement risk — specifically the potential for CMS to reduce laboratory testing reimbursement rates, which would directly impact the Diagnostics segment's revenue per test. Additionally, the competitive landscape with Quest Diagnostics remains intense in routine testing, limiting pricing power in the commodity testing market. Biopharma services revenue is also subject to volatility from pharmaceutical industry R&D spending cycles.
Summary
Wall Street's overall stance on LH is constructive, with a Buy consensus and approximately 20% implied upside from analyst price targets. The investment thesis centers on Labcorp's consistent earnings growth, defensive healthcare characteristics, and expanding biopharma services franchise. The primary risks — leverage, reimbursement pressure, and biopharma spending cyclicality — are well-understood and largely priced in at current valuation levels. For healthcare-focused investors, LH offers a compelling combination of defensive revenue stability and above-market earnings growth.
Labcorp Holdings Inc. Frequently Asked Questions
What are the key investment highlights of Labcorp Holdings?
Labcorp Holdings is a global leader in laboratory diagnostics and clinical research services, with FY2025 revenue of $13.95 billion (up 7% YoY) and diluted EPS of $10.46 (up 18.3% YoY). Key investment highlights include a defensive, necessity-driven business model in healthcare laboratory services; consistent double-digit EPS growth through operational leverage and margin expansion; a growing, higher-margin Biopharma Laboratory Services segment supporting pharmaceutical R&D; a Buy analyst consensus with approximately 20% implied upside from average price targets of $303–$311; and 2026 guidance for 4.7%–6% revenue growth. The company's scale — processing millions of tests annually — provides significant competitive advantages in cost efficiency and data-driven diagnostic innovation.
Who are Labcorp's main competitors, and how does it compare?
Labcorp's primary competitor is Quest Diagnostics (DGX), which operates a comparable national clinical laboratory network. Together, Labcorp and Quest dominate the U.S. clinical laboratory market. Labcorp differentiates through its stronger Biopharma Laboratory Services segment — supporting pharmaceutical and biotech drug development — which provides higher margins and a less commoditized revenue stream than routine diagnostic testing. Other competitors include hospital-based laboratory systems and regional laboratory companies. Internationally, Labcorp competes with companies such as Synlab and Sonic Healthcare. Labcorp's FY2025 revenue of $13.95B compares to Quest's approximately $10B, making Labcorp the larger of the two major independent laboratory companies.
Is Labcorp's financial performance healthy?
Labcorp's financial performance is strong from a revenue and earnings growth perspective. FY2025 revenue grew 7% to $13.95 billion, and diluted EPS grew 18.3% to $10.46. The company generated consistent free cash flow supporting debt service and capital returns. The primary financial health concern is the balance sheet: year-end cash of $532.3 million against total debt of $5.58 billion, with a leverage ratio of 2.3x gross debt to EBITDA. This leverage is manageable given Labcorp's stable cash flow generation, but it is elevated relative to some healthcare sector peers and reduces financial flexibility for M&A or unexpected challenges.
Is LH stock currently overvalued or fairly valued?
Based on analyst consensus, LH appears undervalued at current levels. With the stock trading near $260 and analyst average price targets ranging from $284 to $311, the implied upside is approximately 10%–20%. JPMorgan's bullish $330 target implies over 27% upside. The stock trades at a discount to healthcare sector peers partly due to its leverage profile and partly due to market skepticism about reimbursement risk. However, given the company's consistent earnings growth, defensive business characteristics, and improving margin trajectory, many analysts view the current discount as an attractive entry point. The 2026 revenue growth guidance of 4.7%–6% provides near-term earnings visibility.
How has LH stock performed versus peers recently?
LH has generally performed in line with or slightly below the broader healthcare sector over the past year, reflecting the market's concern about leverage and reimbursement risk offsetting the positive earnings growth story. Against Quest Diagnostics (DGX), LH has demonstrated superior revenue growth and earnings momentum, reflecting the benefit of its biopharma services diversification. On a 3-month basis, LH's performance has been influenced by healthcare sector sentiment, interest rate movements (which affect leveraged companies), and pharmaceutical R&D spending updates from major biopharma customers. The stock's Buy consensus and significant implied upside from analyst targets suggest the market may be underappreciating Labcorp's earnings quality.
Are there major catalysts or risks in Labcorp's industry?
Key positive catalysts include continued growth in pharmaceutical R&D outsourcing — particularly clinical trial laboratory services — driven by the expanding biotech pipeline and increasing complexity of drug development. Advances in genomic testing, liquid biopsy, and AI-assisted diagnostics represent high-growth specialty testing opportunities with premium reimbursement. Potential M&A activity in the fragmented laboratory services industry could also create value. Key risks include CMS reimbursement rate changes for clinical laboratory tests, which are reviewed periodically and can reduce per-test revenue; potential slowdown in pharmaceutical R&D spending if biotech funding conditions tighten; and competitive pricing pressure from Quest Diagnostics in routine testing markets.
Have major institutions recently bought or sold LH stock?
Institutional ownership of LH is broad, with major healthcare-focused asset managers and index funds holding significant positions. The Buy consensus from 9–23 analysts (depending on coverage universe) reflects widespread institutional interest. JPMorgan's $330 price target (February 2026) and the general Buy consensus suggest active institutional conviction in the stock. Income-oriented and dividend growth investors are attracted by Labcorp's consistent dividend payments and EPS growth trajectory. Some value-oriented healthcare investors have increased positions given the stock's discount to analyst price targets, while growth investors have been attracted by the 18.3% EPS growth in FY2025 and the 2026 revenue growth guidance.
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreStock details
How do I buy stock tokens and trade stock perps on Bitget?
To trade Labcorp Holdings Inc. (LH) and other stock products on Bitget, simply follow these steps: 1. Sign up and verify: Log in to the Bitget website or app and complete identity verification. 2. Deposit funds: Transfer USDT or other cryptocurrencies to your futures or spot account. 3. Find trading pairs: Search for LH or other stock token/stock perps trading pairs on the trading page. 4. Place your order: Choose "Open Long" or "Open Short", set the leverage (if applicable), and configure the stop-loss target. Note: Trading stock tokens and stock perps involves high risk. Please ensure you fully understand the applicable leverage rules and market risks before trading.
Why buy stock tokens and trade stock perps on Bitget?
Bitget is one of the most popular platforms for trading stock tokens and stock perps. Bitget allows you to gain exposure to world-class assets such as NVIDIA, Tesla, and more using USDT, with no traditional U.S. brokerage account required. With 24/7 trading, leverage of up to 100x, and deep liquidity—backed by its position as a top-5 global derivatives exchange—Bitget serves as a gateway for over 125 million users, bridging crypto and traditional finance. 1. Minimal entry barrier: Say goodbye to complex brokerage account opening and compliance procedures. Simply use your existing crypto assets (e.g., USDT) as margin to access global equities seamlessly. 2. 24/7 trading: Markets are open around the clock. Even when U.S. stock markets are closed, tokenized assets allow you to capture volatility driven by global macro events or earnings reports during pre-market, after-hours, and holidays. 3. Maximized capital efficiency: Enjoy leverage of up to 100x. With a unified trading account, a single margin balance can be used across spot, futures, and stock products, improving capital efficiency and flexibility. 4. Strong market position: According to the latest data, Bitget accounts for approximately 89% of global trading volume in stock tokens issued by platforms such as Ondo Finance, making it one of the most liquid platforms in the real-world asset (RWA) sector. 5. Multi-layered, institutional-grade security: Bitget publishes monthly Proof of Reserves (PoR), with an overall reserve ratio consistently exceeding 100%. A dedicated user protection fund is maintained at over $300 million, funded entirely by Bitget's own capital. Designed to compensate users in the event of hacks or unforeseen security incidents, it is one of the largest protection funds in the industry. The platform uses a segregated hot and cold wallet structure with multi-signature authorization. Most user assets are stored in offline cold wallets, reducing exposure to network-based attacks. Bitget also holds regulatory licenses across multiple jurisdictions and partners with leading security firms such as CertiK for in-depth audits. Powered by a transparent operating model and robust risk management, Bitget has earned a high level of trust from over 120 million users worldwide. By trading on Bitget, you gain access to a world-class platform with reserve transparency that exceeds industry standards, a protection fund of over $300 million, and institutional-grade cold storage that safeguards user assets—allowing you to capture opportunities across both U.S. equities and crypto markets with confidence.